PulseSight Therapeutics
PrivateLast Round
Series A
Feb 13, 2025
Total Funding Raised
$52M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
PulseSight Therapeutics is a biotechnology company developing non-viral vectorized therapies for severe retinal diseases, with a focus on age-related macular degeneration (AMD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PulseSight Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
PulseSight Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 13, 2025 | ||||
| Seed | Feb 28, 2024 | ||||
| Series B Extension | Aug 4, 2021 | ||||
| Series B | Jan 8, 2020 | ||||
| Series A | Sep 16, 2016 |
Key People
Founding team and executive leadership
PulseSight Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Korea Investment Partners | Seed, Series A, Series B Extension |
| Inserm Transfert | Series A, Series B |
| Pontifax Venture Capital | Series A, Series B |
| Bpifrance | Series A, Series B |
| +ND Capital | Series A, Seed |
| Pureos Bioventures | Series B, Series A, Seed |
| Boehringer Ingelheim Venture Fund | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 24, 2026
Monthly visitors grew 50% MoM.
- Apr 23, 2026
Will present at the ARVO 2026 annual meeting in Denver.
PulseSight Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about PulseSight Therapeutics's valuation, stock price, and market status.